Injectable, biodegradable microspheres form a successful system for parenteral drug delivery.

Relying on micro-encapsulation process technologies developed in-house and through technology partnerships, InnoCore is capable of producing injectable microsphere formulations with controlled particle size (typically 20-50 micron) that are suitable for sustained release of active components from a few weeks up to over 6 months. InnoCore has proven its success in manufacturing these spherical microparticles for a variety of pharmaceutical compounds, such as antibiotic drugs, hormones, antibodies and peptides like LHRH-agonists.

To create next generation microsphere drug delivery products with competitive features and improved patient compliance, InnoCore has established strategic R&D collaborations focused on micro-encapsulation process technology for the manufacturing of monodisperse microspheres, microspheres with improved protein stability and continuous manufacturing processes to replace the commercially less viable batch-wise micro-encapsulation processes.

Monodispersed microspheres and full control over particle size with smooth injectability
Biodegradable and proven safe polymers
Initial burst control
Suitable for a variety of compounds, including proteins, peptides and small molecules
Full control over release profile by diffusion, zero order kinetics
High encapsulation efficiency (> 85%)
High loadings (up to 50%)
Continuous manufacturing process
Early phase development, upscaling and manufacturing in house
Strong patent position in polymer composition as well as processing

Read more about InnoCore’s patented SynBiosys® technology here.